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Inducingmemory CD8+ T cells specific for conserved
antigens from influenza A virus (IAV) is a potential
strategy for broadly protective vaccines. Here we
show that memory CD8+ T cells in the airways played
an important role in early control of IAV. Expression
of the chemokine receptor CXCR3 was critical for
memory CD8+ T cells to populate the airways during
the steady state and vaccination approaches were
designed to favor the establishment of memory
CD8+ T cells in the airways. Specifically, we found
that interleukin-12 (IL-12) signaling shortly after im-
munization limited CXCR3 expression on memory
CD8+ T cells. Neutralization of IL-12 or adjuvants
that did not induce high amounts of IL-12 enhanced
CXCR3 expression, sustained airway localization of
memory CD8+ T cells, and resulted in superior pro-
tection against IAV.
INTRODUCTION
Antibody-inducing influenza A virus (IAV) vaccines are available
but protection is suboptimal (Osterholm et al., 2012) and requires
annual reformulation of the vaccine. IAV can escape neutraliza-
tion by preexisting antibodies because of the high rate of muta-
genesis in the primary targets of neutralization (hemagglutinin
[HA] and neuraminidase [NA]) and because of its capacity to
recombine in nonhuman hosts. In the absence of neutralizing
antibodies, memory CD8+ T cells specific for epitopes located
in conserved regions of IAV proteins like the internal components
nucleoprotein (NP), polymerase A, andmatrix proteinmay confer
protection (Christensen et al., 2000; Heiny et al., 2007; Liang
et al., 1994). However, the contribution of memory CD8+
T cells to protection against IAV is still under debate, because
vaccination or previous IAV exposure does not protect from sub-
sequent heterosubtypic IAV infection (Steinhoff et al., 1993; Wil-
kinson et al., 2012). Boosting the numbers of broadly protective
memory CD8+ T cells may be a strategy to bolster their protec-
tive capacity (Slu¨tter et al., 2013), but little is known about the
functional requirements for robust CD8+ T cell-mediated protec-
tion against IAV. Memory CD8+ T cells constitute a very hetero-Igeneous population, in terms of their capacity to proliferate and
to generate cytokines and/or cytolytic mediators and the tissues
in which they reside (Jameson and Masopust, 2009). For
instance, multifunctional memory CD8+ T cells that produce
IFN-g, TNF-a, and IL-2 after restimulation are generally associ-
ated with more robust proliferation and protection against viral
infections (Nolz and Harty, 2011; Seder et al., 2008). Additionally,
variation in the expression of selectins, integrins, and chemokine
receptors leads to differential migratory patterns and localization
of memory CD8+ T cells (Gebhardt and Mackay, 2012; Hikono
et al., 2007; Sallusto et al., 1999), which can impact their protec-
tive capacity (Jiang et al., 2012). Determining the optimal mem-
ory CD8+ T cell characteristics for protection against IAV and
understanding how such memory could be generated will be
crucial to future influenza vaccine development.
Here we report that the cytokine milieu evoked during primary
or booster immunization can greatly influence the protective ca-
pacity of memory CD8+ T cells against IAV by altering CXCR3
expression and the capacity of memory CD8+ T cells to survey
the respiratory tract.
RESULTS
The Protective Capacity of IAV-Specific Memory CD8+
T Cells Is Shaped by the Booster Agent
We previously reported an accelerated prime-boost strategy
to induce large numbers of memory CD8+ T cells (Badovinac
et al., 2005; Pham et al., 2010; Schmidt et al., 2008) and adopted
this protocol to establish a large NP-specific memory CD8+
T cell population. Priming BALB/c mice with mature dendritic
cells coated with the H2-Kd-restricted NP147-155 epitope (DC-
NP147) and boosting with attenuated Listeria monocytogenes
expressing IAV NP (LM-NP) resulted in a large memory CD8+
T cell population (Figure S1A available online), which was suffi-
cient to protect mice from a lethal A/PR/08/34 (PR8) infection
(Figure S1B). Depletion of CD8+ T cells prior to challenge
rendered prime-boosted mice completely susceptible to lethal
PR8, demonstrating that protection was CD8+ T cell mediated
(Figure S1B).
To assess whether the booster agent influences the protec-
tive capacity of memory NP-specific CD8+ T cells, DC-
NP147-primed mice were boosted with LM-NP or vaccinia
virus expressing NP (VV-NP). LM-NP and VV-NP boosting re-
sulted in similar high frequencies of NP147-specific memorymmunity 39, 939–948, November 14, 2013 ª2013 Elsevier Inc. 939
Figure 1. Boosting with LM and VV Results
in NP-Specific CD8+ T Cell Memory Popula-
tions of Similar Size but Differential Ability to
Protect against IAV Infection
(A) BALB/c mice were primed with DC coated with
NP147 and boosted 1 week later with either LM-
NP or VV-NP. Percentage of circulating NP147-
specific CD8+ T cells was determined 45 days after
boost. Each dot represents a single mouse.
(B) The prime-boosted mice and naive mice were
challenged with a lethal dose of PR8. Morbidity
was assessed daily and the number of surviving/
total challenged mice are indicated.
(C) Viral titers in lung were determined at day 2, 4,
and 6 after infection.
n = 5 ± SEM, representative of four experiments;
*p < 0.05. Also see Figure S1.
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CXCR3hiCD8+ T Cells in Airways Protect against IAVCD8+ T cells in blood (Figure 1A). However, although LM-NP-
and VV-NP-boosted mice both survived lethal infection with
PR8, the VV-NP-boosted mice exhibited less morbidity and
recovered more rapidly than did their LM-NP-boosted counter-
parts (Figure 1B). This suggested that VV-NP-boosted mice
more effectively controlled the IAV infection. Indeed, as early
as 2–4 days after IAV infection, the viral titer in the lungs of
VV-NP-boosted mice was significantly lower than in the lungs
of LM-NP-boosted mice (p < 0.05, Figure 1C). Thus, despite
inducing a similar frequency of IAV-specific memory CD8+
T cells in the blood, VV-NP boosting provided superior protec-
tion and accelerated viral clearance compared to LM-NP
boosting.
The superior protection of VV-NP-boostedmicewas notmedi-
ated by CD4+ T cells or NP-specific antibodies as shown by the
fact that CD4+ T cell depletion of VV-NP-boosted mice or trans-
fer of serum containing NP-specific antibodies to LM-NP-
boosted mice prior to lethal infection did not affect protection
against IAV (Figures S1C and S1D). In contrast, depletion of
CD8+ T cells prior to IAV challenge rendered both LM-NP- and
VV-NP-boosted mice completely vulnerable to lethal PR8 infec-
tion (Figure S1E). To determine whether the NP147-specific
CD8+ T cells from LM-NP- and VV-NP-boosted mice have a
different protective capacity against IAV, CD8+ T cell-enriched
splenocytes from both groups were transferred and recipient
mice were challenged with a lethal dose of PR8. Although the
CD8+ T cell recipient mice lost substantially more weight after
challenge than those that were prime boosted (Figure 1B), trans-
fer of 3 3 105 NP147-specific memory CD8+ T cells from VV-
NP-boosted mice was sufficient to protect mice from lethal IAV
infection. In contrast, transfer of the same number of LM-NP-
boosted memory CD8+ T cells was not protective (Figures S1F
and S1G). Therefore, these data show that VV-NP boosting
resulted in memory CD8+ T cells that were, on a per cell basis,
more protective against IAV infection than those that were
induced by LM-NP boosting.
Similar Function but Different Localization of LM-NP-
and VV-NP-Boosted Memory CD8+ T Cells
CD8+ T cells can provide protection by killing infected cells and
through production of cytokines. Variation in amounts of serine
proteases like GranzymeB and/or a differential ability to produce
cytokines could explain the superior protective capacity of940 Immunity 39, 939–948, November 14, 2013 ª2013 Elsevier Inc.VV-NP-boosted IAV-specific memory CD8+ T cells. However,
after peptide stimulation, similar frequencies of LM-NP- and
VV-NP-boosted NP147-specific memory CD8+ T cells produced
IFN-g, TNF-a, and IL-2 (Figure S2A), exhibited no difference in
Granzyme B expression (Figure S2B), and exhibited similar anti-
gen sensitivity for cytokine production, when obtained from the
spleen (Figure S2C) as well as the lung (data not shown). This
suggests that LM-NP and VV-NP boosting resulted in memory
CD8+ T cells with a similar capacity to kill infected cells and pro-
duce cytokines.
Because we found no differences in circulating CD8+ T cell
numbers and effector functions, we next evaluated the distribu-
tion of the memory populations. Along with similar frequencies
in the blood, we observed equal numbers of NP147-specific
CD8+ T cells in the spleen (Figure 2A). Moreover, perfused
lungs, which may still contain CD8+ T cells in lung capillary
beds (Anderson et al., 2012), had similar total numbers of
NP147-specific CD8+ T cells in LM-NP- and VV-NP-boosted
mice. In contrast, we found 73 more NP147-specific CD8+
T cells in bronchoalveolar lavage (BAL) fluid from VV-NP-
boosted mice compared to that from LM-NP-boosted mice
(p < 0.05, Figure 2A). Thus, because the cellular contents of
the BAL fluid correlates with the cellular contents of the airways
(Papiris et al., 2005; Weiland et al., 1989), LM-NP and VV-NP
boosting resulted in differential localization of memory CD8+
T cells, with VV-NP boosting favoring the establishment of
memory CD8+ T cells lining the airways.
Although we consistently observed significantly more
NP147-specific memory CD8+ T cells in the BAL after VV-NP
boosting, the recovered numbers were low. This was probably
due in part to inefficient recovery of respiratory CD8+ T cells
during BAL lavage and thus these numbers were probably a
substantial underestimate of the actual populations. To assess
whether the NP147-specific memory CD8+ T cells lining the air-
ways mediated the enhanced protection against IAV, we devel-
oped a local depletion strategy that drastically decreased the
number CD8+ T cells recovered by BAL but did not affect the
total number of CD8+ T cells recovered from the lung (Fig-
ure 2B). LM-NP- and VV-NP-boosted memory mice were
treated with control IgG or 5 mg aCD8 intranasally, followed
48 hr later by lethal infection with PR8. Strikingly, intranasal
aCD8 treatment enhanced morbidity (Figure 2C) and increased
viral titers (Figure 2D) in VV-NP-boosted mice such that they
Figure 2. NP147-Specific Memory CD8+
T Cells in the Airway Mediate Early Control
of IAV Infection
(A) Number of NP147-specific CD8+ T cells in
blood, spleen, lung, and airways determined by
tetramer analysis at day 50 after boosting with
either LM-NP or VV-NP.
(B) VV-NP-boostedmemorymice received 5 mg rat
IgG or aCD8 intranasally. After 24 hr, CD8 T cells in
BAL fluid and lungs were analyzed by staining for
Thy1.2 and CD8b.
(C and D) LM-NP- and VV-NP-boosted memory
mice received 5 mg rat IgG or aCD8 intranasally.
After 48 hr mice were challenged with a lethal dose
of PR8. Morbidity was assessed daily (C) and viral
titers were determined 4 days after infection (D).
n = 5 ± SEM, representative of three experiments;
*p < 0.05. Also see Figure S2.
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CXCR3hiCD8+ T Cells in Airways Protect against IAVresembled Ig-treated LM-NP-boosted mice. However,
morbidity and viral clearance in LM-NP-boosted memory
mice, which contained very few NP147-specific CD8+ T cells
in the airways at the time of challenge, was not affected by
local CD8+ T cell depletion. This is consistent with CD8+
T cells in or lining the airways mediating the additional protec-
tion observed in VV-NP-boosted mice.
IAV-specific memory CD8+ T cells situated in or in close
proximity to the airways could be perfectly located to detect
infection early and remove infected cells, thereby limiting viral
replication. Additionally, the number of these cells may rapidly
increase through local proliferation (C¸uburu et al., 2012) or
enhanced recruitment of additional memory CD8+ T cells
from the systemic circulation (Schenkel et al., 2013). To assess
whether protection in VV-NP-boosted mice is mediated by the
pre-existing memory CD8+ T cells in the airways or through
rapid proliferation or migration, the number of NP147-specific
CD8+ T cells in the BAL fluid of LM-NP- and VV-NP-boosted
mice was determined during the first 4 days after IAV infection.
Although the number of NP147-specific CD8+ T cells in the BAL
fluid was higher in VV-NP- than in LM-NP-boosted mice
throughout the evaluated time period (Figure S3A), no signifi-
cant increase in either group was observed during this early
period after challenge (p > 0.05), suggesting limited prolifera-
tion or recruitment of CD8+ T cells during the first 4 days after
IAV infection. However, NP147-specific CD8+ T cells in the BAL
rapidly expressed CD69 after IAV infection (Figure S3B), which
suggested recent antigen encounter. Thus, this suggested that
the increased protection by NP147-specific memory CD8+
T cells in VV-NP-boosted mice was mediated through the
pre-existing local memory CD8+ T cell population in the
airways.Immunity 39, 939–948, NMemory CD8+ T Cells Are Recruited
into the Respiratory Tract under
Steady-State Conditions
Havingestablished thatCD8+Tcells in the
airways mediated enhanced protection
against IAV infection,wenext investigated
how VV-NP boosting resulted in a larger
memory CD8+ T cell population in theBAL fluid than did LM-NP boosting. Similar numbers of NP147-
specific CD8+ T cells in the BAL fluid were observed at 8 days af-
ter boosting with LM-NP and VV-NP (Figure 3A). However, this
population contracted more sharply in LM-NP-boosted mice
and resulted in more memory NP147-specific CD8+ T cell in the
respiratory tract of VV-NP-boosted mice by day 20 and beyond
(Figure 3A). These data suggested that either more VV-NP-
boosted memory CD8+ T cells survived the contraction phase
in the BAL fluid and progressed into memory or that more VV-
NP-boosted memory CD8+ T cells continued to traffic into the
airways over time. To address these possibilities, CD8+ T cells
in airways were locally depleted on day 7 after VV-NP boost,
which effectively reduced the effector population in the BAL fluid
on day 8. Despite this early depletion, the NP147-specific mem-
ory CD8+ T cell population at day 40 after depletion in the airways
was similar to thememory populations found in control Ig-treated
VV-NP-boosted animals (Figure 3B). This suggested that airway
memory CD8+ T cells were not resident memory (Jiang et al.,
2012; Masopust et al., 2006) but were continually repopulating
the airways under steady-state conditions.
To directly determine whether memory CD8+ T cells can traffic
to the airways from the circulation during the steady state, T cells
from spleens of LM-NP- and VV-NP-boostedmemorymice were
transferred intravenously into naive recipients. Within days after
transfer, donor CD8+ T cells were detected in the BAL fluid (Fig-
ure 3C), showing that memory CD8+ T cells could traffic into the
respiratory tract during the steady state. Consistent with the re-
sults in immunizedmice, more transferred VV-NP-boosted CD8+
T cells were detected in BAL fluid than LM-NP-boosted CD8+
T cells, suggesting the VV-NP-boosted memory CD8+ T cells
had a superior ability to traffic to the respiratory tract under
steady-state conditions.ovember 14, 2013 ª2013 Elsevier Inc. 941
Figure 3. Memory CD8+ T Cells Derived from VV-NP-Boosted Mice
Traffic to the Airways More Efficiently than Do Memory CD8+ T Cells
from LM-NP-Boosted Mice
(A) Number of NP147-specific CD8+ T cells in BAL fluid at the indicated days
after LM-NP or VV-NP boost.
(B) VV-NP-boostedmice received 5 mg rat IgG or aCD8 intranasally 6 days after
boost. Number of NP147-specfic CD8+ T cells in the BAL fluid was determined
at the indicated time points.
(C) Splenocytes containing equal numbers of NP-specific memory CD8+
T cells (Thy1.2) from LM-NP- or VV-NP-boosted mice were transferred into
Thy1.1 recipients. Total numbers of NP147-specific CD8+ T cells in the BAL
fluid and lungs were determined 5 days after transfer.
Mean n = 5 ± SEM, representative of two experiments; *p < 0.05. Also see
Figure S3.
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CXCR3hiCD8+ T Cells in Airways Protect against IAVCXCR3 Mediates Memory CD8+ T Cell Trafficking into
the Airways under Steady-State Conditions
The observation that memory CD8+ T cells could traffic into the
airways during the steady state prompted us to investigate the
requirements for memory CD8+ T cells to reach the BAL fluid.
Analysis of a variety of surface molecules associated with
T cell migration such as CD44, core 2 O-glycosylated CD43
(1B11), CD62L, CD103, CXCR3, and CCR5 show that NP147-
specific memory CD8+ T cells in the BAL fluid were exclusively
CD44hi, CD62Llo, CD103lo (Figure S4), and CXCR3hi (Figure 4A).
Of note, the uniform CXCR3 expression on NP147-specific
CD8+ T cells in the BAL fluid was distinct from the fraction of
cells expressing CXCR3 in the spleen (Figure 4A). Moreover,
expression of CXCR3 was significantly (p > 0.05) higher on
VV-NP-boosted than in LM-NP-boosted circulating memory
CD8+ T cells (Figure 4B) and the CXCR3hi cells were also VLA-
1hi (Figure S4B), indicative of a lung tropism (Ray et al., 2004).
These data strongly suggested a role for CXCR3 in the localiza-
tion of memory CD8 T cells to the respiratory tract and may
potentially explain the superior numbers in the BAL of VV-NP-
boosted mice.942 Immunity 39, 939–948, November 14, 2013 ª2013 Elsevier Inc.Therefore we next asked whether CXCR3 expression is
required to establish a memory CD8+ T cell population in the res-
piratory tract. LM and VV boosting in C57BL/6 mice led to similar
differences in CXCR3 expression on memory CD8+ T cells as in
BALB/c mice (data not shown). Therefore, we switched to
C57BL/6 mice, enabling us to use P14 transgenic CD8+ T cells
and IAV expressing the GP33 epitope. Wild-type (WT) and
Cxcr3/ P14 memory CD8+ T cells were generated through
DC-GP33 prime and VV-GP33 boosting, ensuring that the WT
P14 were CXCR3hi (data not shown). At a memory time point,
similar numbers of WT and Cxcr3/ P14 were detected in the
spleen and lung, but significantly (p > 0.05) more WT memory
P14 were found in the BAL fluid compared to Cxcr3/ memory
P14 (Figure 4C). Thus the absence of CXCR3 impaired the for-
mation of a memory CD8+ T cell population in the airways.
Second, we asked whether CXCR3 plays a direct role in the
trafficking of memory P14 to the BAL under steady-state condi-
tions. To address this we transferred a 1:1 mixture of WT and
Cxcr3/ memory P14 into the same recipients and analyzed
the distribution of these populations in the spleen, lung, and
BAL fluid after 5 days (Figure 4D). WTmemory P14 had amarked
advantage for accumulating in the BAL fluid, whereas equal
numbers of WT and Cxcr3/ P14 were recovered from the
spleen and perfused lung. Because VLA-1 expression was pro-
nounced on CXCR3hi cells (Figure S4B) and VLA-1 (a1b1 integ-
rin) has been implicated in the localization of memory CD8+
T cells to airways (Ray et al., 2004), this integrin may provide
an alternative explanation for the decreased accumulation of
Cxcr3/memory P14. However, no difference in VLA-1 expres-
sion of WT and Cxcr3/ memory P14 was observed (Fig-
ure S4C). Finally, Cxcr3/ memory P14 were significantly less
able to control IAV-expressing GP33 than were WT memory
P14 (p < 0.01) (Figure 4E). Overall, these data established that
CXCR3 was directly involved in localization of memory CD8+
T cells to the airways under steady-state conditions.
CXCR3 ligands CXCL9 and CXCL10 are IFN-g-inducible che-
mokines and are highly expressed in inflamed tissue. Whether
these ligands are present in lung tissue during the steady state
is unclear. By using IFN-g-deficient mice as a negative control,
we showed that a large fraction of wild-type C57BL/6 mice con-
tained detectable Cxcl9, Cxcl10, and IfngmRNA in their lungs as
detected by qPCR (Figure S4D), indicating that IFN-g-inducible
chemokines could play role in the accumulation of CD8+
T cells in the airways during the steady state.
IL-12 Signaling Diminished CXCR3 Expression on
Memory CD8+ T Cells and Localization to the Airways
Differential CXCR3 expression between LM-NP- and VV-NP-
boosted mice could play a critical role for trafficking of memory
CD8+ T cells to BAL and subsequent protection against IAV. A
major difference between LM and VV is the inflammatory milieu
they generate upon infection (Keppler et al., 2012; Wirth et al.,
2011). Specifically, LM infection drove substantially higher
serum amounts of IL-12 and type I interferons than did VV infec-
tion (Figure S5A). To address whether these cytokines modu-
lated CXCR3 expression on memory CD8+ T cells, WT, IL-12
receptor-deficient (Il12rb1/), and type I interferon receptor-
deficient (Ifnar1/) B6 mice were primed with DC-OVA257 and
infected with attenuated LM-expressing ovalbumin (LM-OVA).
Figure 4. CXCR3 Expression Mediates
Memory CD8+ T Cell Migration to the BAL
and Enhances Protection against IAV
(A) CXCR3 expression on NP147-specific memory
CD8+ T cells in the BAL, lung, and spleen of VV-
NP-boosted mice.
(B) CXCR3 expression on NP147-specific memory
CD8+ T cells in the PBL.
(C) A total of 5,000 P14 or 5,000Cxcr3/P14were
transferred into naive recipients. Mice were primed
with DC-GP33 and boosted with VV-GP33.
Numbers of P14 in the BAL fluid, lung, and spleen
were quantified at day 40 after boost.
(D) A total of 106 wild-type (Thy1.1/1.1) and
Cxcr3/ memory P14 (Thy1.1/1.2) were trans-
ferred in a 1:1 ratio to naive recipients. After 5 days
the ratio of WT:Cxcr3/ P14 was determined in
the spleen, lung, and BAL.
(E) Wild-type and Cxcr3/ memory P14 gener-
ated by priming with DC-GP33 and boosting with
either LM-GP33 or VV-GP33 were transferred to
naive recipients and challenged with PR8-GP33.
Viral titers in the lung were determined 3 days after
infection.
Bars represent mean n = 5 ± SEM, representative
of three experiments; *p < 0.01. Also see Figure S4.
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CXCR3hiCD8+ T Cells in Airways Protect against IAVCXCR3 expression on OVA257-specific effector and memory
CD8+ T cells was unaltered in Ifnar1/ mice but was increased
in Il12rb1/ mice when both were compared to WT mice (Fig-
ure 5A). These data suggested that IL-12R signaling reduced
CXCR3 expression on CD8+ T cells. To assess whether this
resulted from CD8+ T cell-intrinsic IL-12 signaling, WT and
Il12rb1/ OT-I T cells were transferred into the same WT hosts,
primed with DC-OVA, and boosted with LM-OVA. A higher frac-
tion of Il12rb1/OT-I expressed CXCR3 than didWTOT-I at the
effector as well as the memory stage (Figure 5B). This demon-
strated that direct IL-12R signaling to CD8+ T cells had a nega-
tive effect on the expression of CXCR3.
To evaluate how signaling downstream of IL-12R leads to
reduction of CXCR3 surface expression, we assessed the role
of STAT4. WT (Thy1.1/1.2) and Stat4/ (Thy1.2/1.2) BALB/c
bone marrow were introduced into irradiated BALB/c recipients
(Thy1.1/1.1) to generate chimeras. After reconstitution, mice
were primed with DC-NP147 and boosted with LM-NP. The
circulating NP147-specific CD8+ T cell populations at day 7
and day 32 after boost were numerically larger for WT-derived
CD8+ T cells (Figure 5C). However, less than 30% of the WT
NP147-specifc CD8+ T cells were CXCR3hi at these time points,
whereas more than 70% of the Stat4/ NP147-specific CD8+
T cells were CXCR3hi (Figure 5C). Additionally, although theImmunity 39, 939–948, Noverall size of the WT NP147-specific
memory population in the spleen and
lung was larger, Stat4/ NP147-specific
memory CD8+ T cells accumulated more
effectively in the airways (Figure 5D).
ChIP-seq experiments have not identi-
fied the CXCR3 promoter as a potential
binding site for STAT4 (Good et al.,
2009), suggesting that the CXCR3-re-pressing effect may be further downstream of this transcription
factor. IL-12 and STAT4 signaling are reported to sustain levels
of the T-box transcription factor T-bet in activated CD8+ T cells
(Takemoto et al., 2006; Yang et al., 2007). Correspondingly, T-
bet expression in LM-NP-boosted NP147-specific memory
CD8+ T cells was higher than in VV-NP-boosted memory CD8+
T cells (Figure S5B). To evaluate the role of T-bet on localization
of memory CD8+ T cells in the airways, heterozygous (Tbx21+/)
and WT (Tbx21+/+) P14 CD8+ T cells were transferred into WT
recipients and prime-boosted with DC-GP33 and LM-GP33. As
reported previously (Joshi et al., 2011), CXCR3 expression in
Tbx21+/ P14 was greatly increased compared to WT P14,
both at an effector as well as at a memory time point (Figure 5E),
demonstrating that high levels of T-bet correlated with reduced
CXCR3 expression on CD8+ T cells. In line with the differences
in CXCR3 expression, Tbx21+/ P14 established a larger mem-
ory population in the BAL fluid compared to Tbx21+/+ P14 (Fig-
ure 5F). Importantly, reduction of T-bet did not decrease the total
number of systemic memory CD8+ T cells, as indicated by the
fact that similar numbers of memory Tbx21+/+ and Tbx21+/
P14were retrieved from spleens >40 days after boost (Figure 5F).
Thus, a reduction in T-bet expression did not affect the size of the
systemic memory P14 population but reduced the expression of
CXCR3 and localization of memory CD8+ T cells in the airways.ovember 14, 2013 ª2013 Elsevier Inc. 943
Figure 5. IL-12 Receptor Signaling Reduced
CXCR3 Expression and Localization to Air-
ways
(A) WT, Il12rb1/, and Ifnar1/ B6 mice were
infected with 106 LM-OVA and CXCR3 expression
onOVA257-specific CD8+ T cells was tracked over
time.
(B) A total of 500WTOT-I (Thy1.2/1.2, CD45.2) and
500 Il12rb1/ OT-1 (Thy1.1/1.2, CD45.2) were
cotransferred and CD45.1 recipients were primed
with DC-OVA and infected on day 7 with 106
LM-OVA. Expression of CXCR3 on OT-1 was
determined at effector (day 7) andmemory (day 45)
time points after boosting.
(C) WT (Thy1.1/1.2) and Stat4/ (Thy1.2/1.2)
BALB/c bone marrow were introduced (in a 1:1
ratio) in irradiated BALB/c mice (Thy1.1/1.1) and
after 2 months, chimeric recipients were primed
with DC-NP147 and boosted with LM-NP. Panels
shown were gated on KdNP147 tetramer-positive
CD8+ T cells. CXCR3 expression on NP147-spe-
cific CD8+ T cells was determined on days 7 and
41 after boost.
(D) At day 35 after boost, the ratios of Stat4/ and
WT NP147-specific CD8+ T cells were determined
in blood, spleen, lung, and BAL fluid.
(E) WT (Tbx21+/+) and Tbx21+/ P14 were trans-
ferred and prime-boosted with DC-GP33 and
LM-GP33. Expression of CXCR3 was assessed at
day 7 and day 41 time points.
(F) At thememory time point, numbers of P14 in the
spleen and BAL were determined.
Bars represent mean n = 5 ± SEM, representa-
tive of three experiments; *p < 0.001. Also see
Figure S5.
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CXCR3hiCD8+ T Cells in Airways Protect against IAVNeutralization of IL-12 Increases Protective Capacity of
IAV Memory CD8+ T Cells
We next assessed whether manipulation of IL-12 signaling dur-
ing boosting enhanced the localization of memory CD8+ T cells
and improved their protective capacity against IAV. Mice were
treated with aIL-12 or control IgG on day 0 and 1 after LM-NP
boost, when serum levels of IL-12 peaked (Figure S5A). Neutral-
ization of IL-12 resulted in no discernable difference in the
NP147-specific CD8+ T cell frequency in the blood (Figures 6A
and 6B). However, neutralization of IL-12 significantly increased
(p < 0.01) the frequency of CXCR3hi NP147-specific CD8+ T cell
both at effector and memory time points (Figures 6A and 6B).
Consistent with this, aIL-12 treatment during LM-NP boost
increased the number of NP147-specific memory CD8+ T cells
in BAL fluid but not spleen or lung (Figure 6C). Finally, mice
treated with aIL-12 during boosting with LM-NP exhibited signif-
icantly lower viral titers (p < 0.001) after challenge with PR8 (Fig-
ure 6D). This showed that neutralization of IL-12 during booster
immunization enhanced localization of the resulting memory
CD8+ T cell population to the airways and increased protection
against IAV.
From a vaccination perspective, it may be more feasible to
avoid using vaccine vectors or adjuvants that induce high sys-
temic IL-12 levels, rather than to neutralize IL-12 after the immu-
nization. Whereas the TLR9 agonist CpG oligonucleotides
triggered a potent IL-12 response, the TLR3 agonist poly(I:C) pri-
marily induced type I IFN (Figure 7A). To assess whether these944 Immunity 39, 939–948, November 14, 2013 ª2013 Elsevier Inc.two adjuvants would induce memory CD8+ T cells with differen-
tial CXCR3 expression and protective capacity against IAV, mice
were vaccinated with DC-OVA adjuvanted with CpG or poly(I:C).
Although adjuvanting with CpG resulted in enhanced numbers
of OVA257-specific CD8+ T cells at an effector time point
compared to adjuvanting with poly(I:C), an equal frequency of
circulating CD8+ T cells was observed at a memory time point
(Figure 7B). Of note, OVA257-specific CD8+ T cells that resulted
from immunization in the presence of CpG expressed signifi-
cantly less CXCR3 at both an effector (p < 0.001, Figure 7C)
and amemory (Figure 7D) time point. Concordantly, the BAL fluid
of poly(I:C)-adjuvanted mice contained a larger number of
OVA257-specific memory CD8+ T cells than did CpG-adju-
vanted mice (Figure 7E). When challenged with a lethal dose of
PR8 expressing OVA257 (PR8-OVA), mice that were immunized
with DC-OVA + poly(I:C) controlled the virus significantly (p <
0.05) better than did naive or DC-OVA + CpG mice (Figure 7E).
Overall, these data demonstrated that the choice of adjuvant
impacted CXCR3 expression, airway localization, and protective
capacity against IAV of the ensuing memory CD8+ T cells.
DISCUSSION
Memory CD8+ T cells could be an important part of heterosub-
typic protection against IAV because they can recognize
conserved epitopes in viral proteins that have not been sub-
jected to immunological pressure (Yewdell et al., 1985; Zweerink
Figure 6. Neutralization of IL-12 during Boost Improves the Protec-
tive Capacity of Memory CD8+ T Cells
DC-NP-primed BALB/c mice were boosted with 106 LM-NP. On the day of
boosting and the day after, mice received aIL-12 (clone C17.8) or control
antibody.
(A) Representative dot plots of NP147-specific CD8+ T cells quantified with
KdNP147 tetramers and CXCR3 expression on the KdNP147-positive cells.
(B) The percentage of NP147-specific CD8+ T cells and their CXCR3 expres-
sion in the blood.
(C) On day 44 after boost, number of NP147-specific CD8+ T cells in the BAL
was determined.
(D) Peak viral titers (day 4) after infection with a lethal dose of PR8.
n = 5 ± SEM, representative of three experiments; *p < 0.05.
Figure 7. CXCR3 Expression, Airway Localization, and Protection by
Memory CD8+ T Cells Can Be Manipulated by Adjuvant Choice
(A) Serum levels of IL-12 and IFN-awere determined after DC-OVA vaccination
adjuvanted with CpG or poly(I:C).
(B) OVA257-specific CD8 T cell response in the blood were tracked over time
by tetramer analysis.
(C) CXCR3 expression on OVA257-specific CD8+ T cells was determined by
flow cytometry on day 7 after vaccination.
(D) At a memory time point (day 60 after vaccination), CXCR3 expression was
reassessed.
(E) The number of OVA257-specific CD8+ T cells in the BAL fluidwas assessed.
(F) Viral titers 4 days after infection with PR8-OVA at a memory time point.
Mean n = 5 ± SEM, representative of two experiments; *p < 0.05.
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detected in humans with a history of IAV infection, immunity pro-
vided by these cells appears to be limited (Wilkinson et al., 2012).
Increasing the number of IAV-specific memory CD8+ T cells
through boosting can improve protection (Christensen et al.,
2000; Slu¨tter et al., 2013), but it is also clear that the boosting
can have a profound effect on the phenotype of the resulting
memory CD8+ T cell population (Wirth et al., 2011). Here we
show that memory CD8+ T cells with a superior protective
capacity against IAV could be generated by manipulating the
cytokine milieu via selection of vaccine vectors or adjuvants.
Therefore, this work may provide a rationale for the development
of future influenza vaccines to induce protective CD8+ T cells.
Increasing the number of IAV-specific memory CD8+ T cells
may be achieved through the use of prime-boost strategies (Slu¨t-
ter et al., 2013), and several potent booster agents capable of
inducing strong CD8+ T cells responses, including adenoviruses,
poxviruses, and attenuated LM strains, are currently under
clinical investigation (Meyer et al., 2013; Sheehy et al., 2012; Sin-
nathamby et al., 2009). Although the focus is generally on maxi-Imizing the number of memory CD8+ T cells, our work argues that
the inflammatory milieu induced by the vaccine vector can also
greatly influence specific properties of memory CD8+ T cells,
including their localization. In turn, our data showed that the
localization of IAV-specific memory CD8+ T cells in the airways
improved their protective capacity. A correlation between local
CD8+ T cell memory in the lung and immunity against IAV infec-
tion has long been established (Liang et al., 1994), but direct
evidence for a protective role of T cells in the respiratory tract
has been reported only for CD4+ T cells (Hogan et al., 2001).
Here we showed, through airway-specific depletion of CD8+
T cells, that IAV-specific memory CD8+ T cells in the airways
substantially lowered the viral burden during the first days of
IAV infection. The generation of amemory CD8+ T cell population
capable of populating the respiratory tract could therefore be an
important goal for next-generation IAV vaccines. In accordance
with the findings of Ely et al. (2006), establishing an airway mem-
ory CD8+ T cell population does not seem to require local immu-
nization or pulmonary inflammation, because memory CD8+
T cells of splenic origin could be detected in the BAL fluid ofmmunity 39, 939–948, November 14, 2013 ª2013 Elsevier Inc. 945
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immunization is therefore not a prerequisite for induction of
respiratory memory CD8+ T cells; parenteral immunization may
lead to an airway-localized memory population. Of note, the
memory CD8+ T cells in the BAL we described were not classical
tissue-resident memory (Trm) as found in the skin (Gebhardt
et al., 2011), intestine (Masopust et al., 2010), or lung paren-
chyma (Wakim et al., 2013) where effector CD8+ T cells are
‘‘educated’’ by the local microenvironment to form resident
memory (Jiang et al., 2012) and provide rapid protection against
reinfection (Jiang et al., 2012). Instead the lung, being a highly
vascularized organ subjected to recurrent environmental expo-
sures, may be more accessible to circulating CD8+ T cells and
allow memory CD8+ T cells subtypes to migrate into the airways
under steady-state conditions.
We showed that CXCR3 was an important chemokine recep-
tor that regulated access into the respiratory tract under steady
state-conditions, whereas Kohlmeier et al. (2008) showed that
CXCR3 expression is dispensable for memory CD8+ T cells to
reach the respiratory tract under inflammatory conditions. Inter-
estingly, Kohlmeier et al. (2008) show that surface expression of
CCR5 on memory CD8+ T cells is low during the steady state but
is quickly upregulated after infection. Together, these data indi-
cate an active role for CCR5 in recruiting memory CD8+ T cells to
the airways during an episode of inflammation whereas during
the steady state its role may be limited. Consistent with this hy-
pothesis, we observed many CXCR3loCD8+ T cells in BAL fluid
7 days after boost with LM-NP (Figure 3A and data not shown),
suggesting CXCR3-independent recruitment. After a few weeks,
however, CD8+ T cells in the BAL fluid were exclusively CXCR3hi
and recruitment to BAL was CXCR3 dependent (Figure 4).
Because the respiratory tract is exposed to frequent environ-
mental stimuli, low levels of IFN-g can be detected in BAL fluid
of healthy humans (Paats et al., 2012), potentially allowing
CXCR3 ligands to be continuously produced. Indeed, we were
able to detect elevated levels of IFN-g, CXCL9, and CXCL10
transcripts in lung tissues from a large subset of mice in
our animal facility. This may provide a gradient sufficient for
CXCR3hiCD8+ T cells to migrate continuously into the respiratory
tract.
The identification of CXCR3 as a pivotal molecule for memory
CD8+ T cells to reach the respiratory tract could help to distin-
guish between high- and low-quality memory CD8+ T cells in
terms of protection against IAV. We showed that the expression
of CXCR3 on CD8+ T cells was tuned by the inflammatory cyto-
kines induced by the vaccine vector or adjuvant. In the case of
CD4+ T cells, CXCR3 is a signature marker associated with a
T helper 1 (Th1) cell phenotype (Sallusto et al., 1998). As such,
IL-12 signaling, STAT4 activation, and T-bet activity are key
events for Th1 cell polarization and promote CXCR3 expression
(Mullen et al., 2001; Thieu et al., 2008). Conversely, we showed
that CXCR3 expression in memory CD8+ T cells was negatively
correlated with IL-12R signaling and T-bet expression. Such dif-
ferential regulation of an important chemokine receptor fits with
previous reports of differential migration of memory CD4+ and
CD8+ T cell to the epidermis (Gebhardt et al., 2011) and lung air-
ways (Ely et al., 2006). Potentially, T-bet directly suppresses
CXCR3 expression in CD8+ T cells as interaction of T-bet with
the promoter region of CXCR3 in human CD4+ T cells has been946 Immunity 39, 939–948, November 14, 2013 ª2013 Elsevier Inc.shown (Beima et al., 2006; Lewis et al., 2007). However, in
CD4+ T cells, T-bet’s interaction with the CXCR3 promoter re-
gion is indisputably positively correlated with CXCR3 expression
(Lewis et al., 2007; Matsuda et al., 2007), suggesting that the
regulation of CXCR3 by T-bet in CD8+ T cells may be indirect.
For instance, T-bet has been reported to promote the expression
of IL-12Rß2 (Afkarian et al., 2002) and as such enhances sensi-
tivity to IL-12.
Although we showed that direct IL-12 signaling to CD8+ T cells
was detrimental to CXCR3 expression, IL-12 is also an important
‘‘signal 3’’ cytokine that promotes optimal accumulation of
effector CD8+ T cells (Curtsinger et al., 2003; Keppler et al.,
2012). In this respect, it is interesting that another major signal
3 cytokine, type I IFN, did not suppress CXCR3 on effector and
memory CD8+ T cells. Therefore, type I IFN could still serve as
the important signal 3 cytokine to allow maximal accumulation
and memory formation of CD8+ T cells (Curtsinger et al., 2003;
Keppler et al., 2012), without reducing their protective capacity
by limiting CXCR3 expression. For instance, the TLR3 agonist
poly(I:C) induces high serum IFN-a levels, but little IL-12, which
may be due to MyD88/IRAK-independent signaling after TLR3
activation (Jiang et al., 2003). We showed as a proof of concept
that the use of poly(I:C) as an adjuvant during DC vaccination led
to a similar number of memory CD8+ T cells as adjuvanting with
TLR9 agonist CpG, but these cells expressed more CXCR3,
localized more effectively to the airways, and had superior pro-
tective capacity against IAV. Selection of adjuvants that induce
little IL-12 but do provide type I IFN may therefore be a relevant
approach to elicit high-quality (CXCR3hi) CD8+ T cells responses
without the drawback of reducing the overall number of memory
CD8+ T cells.
EXPERIMENTAL PROCEDURES
Mice
BALB/c Stat4/, C57BL/6 Il12rb1/, and C57BL/6 Cxcr3/ were acquired
from Jackson Laboratories. C57BL/6 Tbx21/ P14mice have been described
previously (Kaech et al., 2003). Cxcr3/ P14 and Il12rb1/ OT-I mice were
generated through crossingCxcr3/ or Il12rb1/with the respectively trans-
genic mouse strain. C57BL/6 Ifnar1/mice were a gift fromM. Mescher (U. of
Minnesota, Minneapolis, MN). BALB/c and C57BL/6 mice strains were
originally derived from the National Cancer Institute (Fredericksburg, MD)
and a colony is maintained in house. All animal studies and procedures were
approved by the University of Iowa Animal Care and Use Committee, under
PHS assurance, Office of Laboratory Animal Welfare guidelines.
Infections, Vaccine Vectors, and Adjuvants
actA/inlB double-deficient L. monocytogenes expressing IAV NP were
provided by P. Lauer (Aduro Biotech) and actA-deficient LM expressing
LCMV GP33 or OVA were provided by H. Shen (UPenn, Philadelphia, PA)
and were propagated as described (Corbin and Harty, 2004). Vaccinia
virus-expressing LCMV GP33 and IAV NP were provided by J. Bennink
(NIH, Bethesda, MD) and were propagated by standard protocols. For immu-
nization, LM and VV were diluted in phosphate-buffered saline and injected
intravenously. A/PR/08/34 virus was grown in chicken eggs as previously
reported (Legge and Braciale, 2005). While lightly anesthetized, mice were
challenged with a 10-fold LD50 (2 3 105 TCID50) in 50 ml PBS. All infected
mice were monitored daily for morbidity, and mice losing 30% or more of
initial body weight were euthanized per IACUC guidelines and considered
to have succumbed to infection. Viral titers were defined as tissue culture
infective dose 50 (TCID50) by titration on MDCK cells (Slu¨tter et al., 2013).
CpG ODN (IDT) and poly(I:C) (InVivogen) were injected intraperitoneally at
100 mg.
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For systemic depletion of CD4+ T cells, two doses of 400 mg aCD4 (clone
GK1.5) were injected intraperitonial (i.p.). Systemic depletion of CD8+ T cells
required one i.p. injection of 100 mg aCD8 (clone 2.43). Local depletion of
CD8+ T cells from the BAL was achieved through intranasal administration
of 5 mg aCD8. IL-12 was neutralized through two i.p. injections of 400 mg of
aIL-12 (clone C17.8). Control mice received an equivalent amount of rat IgG
in each experiment. All hybridoma cell lines were acquired from ATCC and
purified antibodies were prepared via standard methods.
Adoptive Transfer
For generation of CD8+ T cells, memory, naive OT-I, or P14 transgenic T cells
(Thy1.1+) were obtained from donor blood and were transferred (500 and
5,000, respectively) into naive (Thy1.2+) hosts. Dendritic cell vaccination was
performed with LPS-matured dendritic cells prepared as described (Schmidt
et al., 2009) and coated with NP147-155, GP33-41, or OVA257-264 peptide.
For priming, 5 3 105 DCs were injected intravenously. CpG ODN 1826 and
poly(I:C) were injected intraperitonally (100 mg). For transfer of memory CD8+
T cells, memory P14 were isolated from donor spleens though positive selec-
tion on Th1.1 with magnetic beads (Mylteni). NP147-specific memory CD8
T cells were enriched by depletion of CD4+ andCD19+ cells bymagnetic beads
(Mylteni).
T Cell Analysis
Bronchoalveolar lavage was performed postmortem by inflating the lung
with 1 ml of RPMI 33 through the trachea. Lungs were isolated after sys-
temic perfusion with saline and collegenase/DNase treated for 1 hr prior to
homogenization.
Blood, BAL, and homogenized lung, lymph nodes, and spleens were
depleted of erythrocytes by treatment with ammonium chloride buffer and
stained with the appropriate antibodies or in-house-prepared Kd-NP147
tetramer complexes. All antibodies (aCXCR3 clone CXCR3-173, aCD8a clone
53-6.7, aCD8b clone YTS156.7.7, aThy1.2 clone 53-2.1, and aThy1.1 clone
OX-7) were acquired from Biolegend. Flow cytometry was performed with a
Fortessa flow cytometer (BD Biosciences) and analyzed by FlowJo (Treestar)
for MacIntosh.
Statistics
Unless indicated otherwise, significance was calculated by one-way ANOVA
with Bonferroni’s posttest in Graphpad Prism 4 for Macintosh. p values lower
0.05 were considered significant.SUPPLEMENTAL INFORMATION
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